Wilson Sonsini Goodrich & Rosati advised Cajal Neuroscience on the deal. Cajal Neuroscience Inc., a biotechnology company integrating human genetics, functional genomics, and advanced microscopy to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Inscopix on the deal. Bruker Corporation, a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Enliven Therapeutics on the deal. Enliven Therapeutics, a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Obsidio on the deal, while Latham & Watkins represented Boston Scientific Corporation. Boston Scientific Corporation announced the acquisition of Obsidio, Inc.,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Kedalion Therapeutics on the deal. Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Apexigen on the deal. Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Cellino on the deal. Cellino Biotech, an autonomous cell therapy manufacturing company, announced the completion of a Series A financing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised Current Health on the deal. Best Buy announced it had signed an agreement to acquire Current Health,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Totient on the deal. AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced the acquisition...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised InSilico Medicine on the deal. Ashurst represented Mirae Asset Capital. Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial...
You must be a Standard 1 Year member to access this content.
